Finding new antiviral treatments for COVID-19
Discovery of SARS-CoV-2 antivirals using a replicon assay
['FUNDING_R01'] · EMORY UNIVERSITY · NIH-11111915
This study is looking for new medicines to help fight COVID-19 by testing different compounds that can stop the virus from making copies of itself, so we can have more treatment options beyond what's currently available.
Quick facts
| Phase | ['FUNDING_R01'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | EMORY UNIVERSITY (nih funded) |
| Locations | 1 site (ATLANTA, UNITED STATES) |
| Trial ID | NIH-11111915 on ClinicalTrials.gov |
What this research studies
This research focuses on discovering new antiviral agents to combat SARS-CoV-2, the virus responsible for COVID-19. By utilizing advanced replicon assays and high-throughput screening methods, the team aims to identify effective compounds that can inhibit the virus's replication. The study involves creating specialized cell lines that express the virus's replicon, allowing for rapid testing of potential antiviral candidates. The goal is to enhance treatment options beyond the currently available antiviral, Remdesivir.
Who could benefit from this research
Good fit: Ideal candidates for this research include individuals who are at risk of severe COVID-19 or those who have tested positive for SARS-CoV-2.
Not a fit: Patients who are not infected with SARS-CoV-2 or those who have already recovered from COVID-19 may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to the development of new antiviral medications that significantly improve outcomes for COVID-19 patients.
How similar studies have performed: Other research efforts have successfully identified antiviral agents for similar viruses, indicating a promising potential for this approach.
Where this research is happening
ATLANTA, UNITED STATES
- EMORY UNIVERSITY — ATLANTA, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: SARAFIANOS, STEFAN G — EMORY UNIVERSITY
- Study coordinator: SARAFIANOS, STEFAN G
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.